Previous 10 | Next 10 |
home / stock / jnj / jnj articles
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a...
Johnson & Johnson’s (NYSE:JNJ) medical device subsidiary is pulling its Megadyne Mega Soft Pediatric Patient Return Electrodes follo...
The first-quarter results of the healthcare sector have been unimpressive, with earnings of 78% of the sector participants that have reported so fa...
On Sunday, Johnson & Johnson (NYSE:JNJ) ) released updated results from an open-label, multicenter, multi-cohort Phase 1 st...
In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this ar...
U.S. stocks look to push ahead on a positive path, now that the Federal Reserve’s rate decision is in the rearview mirror. Major index future...
Wednesday, Johnson & Johnson (NYSE:JNJ) announced its intention to proceed with a $6.475 billion settlement to resolve numerous lawsu...
Monday, Addex Therapeutics (NASDAQ:ADXN) released top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-4041181...
Editor’s note: We have updated the story with Kenvue’s statement in response to the report in paragraph 7 The World Health Organiz...
News, Short Squeeze, Breakout and More Instantly...
Assa Abloy AB ADR (ASAZY) is expected to report for Q2 2024 First Horizon Corporation (FHN) is expected to report $0.37 for Q2 2024 Community Trust Bancorp Inc. (CTBI) is expected to report $1.03 for Q2 2024 Cohen & Steers Inc (CNS) is expected to report for Q2 2024 First Indu...
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2024 of $1.24 per share on the company’s common stock. The dividend is payable on September 10, 2024 to shareholders of record at the close of business on Aug...
SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (&...